The genomic regulatory programmes that underlie human organogenesis are poorly understood. Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer and diabetes. We have now characterized the regulatory landscape of embryonic multipotent progenitor cells that give rise to all pancreatic epithelial lineages. Using human embryonic pancreas and embryonic-stem-cell-derived progenitors we identify stage-specific transcripts and associated enhancers, many of which are co-occupied by transcription factors that are essential for pancreas development. We further show that TEAD1, a Hippo signalling effector, is an integral component of the transcription factor combinatorial code of pancreatic progenitor enhancers. TEAD and its coactivator YAP activate key pancreatic signalling mediators and transcription factors, and regulate the expansion of pancreatic progenitors. This work therefore uncovers a central role for TEAD and YAP as signal-responsive regulators of multipotent pancreatic progenitors, and provides a resource for the study of embryonic development of the human pancreas.
The human genome sequence contains instructions to generate a vast number of developmental programmes. This is possible because each developmental cellular state uses a distinct set of regulatory regions. The specific genomic programmes that underlie human organogenesis, however, are still largely unknown 1, 2 . Knowledge of such programmes could be exploited for regenerative therapies, or to decipher developmental defects underlying human disease.
The pancreas hosts some of the most debilitating and deadly diseases, including pancreatic ductal adenocarcinoma and diabetes mellitus. Classic mouse knockout models and human genetics have uncovered multiple transcription factors (TFs) that regulate embryonic formation of the pancreas 3, 4 . For example, GATA6 (GATA binding protein 6; refs 5-7), PDX1 (pancreatic and duodenal homeobox 1; refs 8,9), HNF1B (HNF1 homeobox B; ref. and PTF1A (pancreas specific transcription factor, 1a; ref. 15) are essential for the specification of pancreatic multipotent progenitor cells (MPCs) that arise from the embryonic gut endoderm, or for their subsequent outgrowth and branching morphogenesis. However, little is known concerning how these pancreatic TFs are deployed as regulatory networks, or which genomic sequences are required to activate pancreatic developmental programmes.
One obvious limitation to studying the genomic regulation of human organogenesis lies in the restricted access and the difficulties of manipulating human embryonic tissue. Theoretically, this can be circumvented by using human embryonic stem cells (hESCs) to derive cellular populations that express organ-specific progenitor markers, although it is unclear if such cells can truly recapitulate broad genomic regulatory programmes of genuine progenitors.
In the current study, we dissected pancreatic buds from human embryos and used hESCs to create stage-matched pancreatic progenitor cells. We processed the two cellular sources in parallel and validated in vitro MPCs as a model to study gene regulation in early pancreas development. We created an atlas of active transcripts and enhancers in human pancreatic MPCs, and mapped the genomic binding sites of key pancreatic progenitor TFs. Using this resource, we show that TEA domain (TEAD) factors are integral components of the combination of TFs that activates stage-and lineage-specific pancreatic MPC enhancers.
RESULTS

Regulatory landscape of in vivo and in vitro MPCs
To study the genomic regulatory programmes of the nascent embryonic pancreas, we dissected pancreatic buds from Carnegie stage (CS) 16-18 human embryos. At this stage, the pancreas has a simple epithelial structure formed by cells expressing markers of pancreatic MPCs (including PDX1, HNF1B, FOXA2, NKX6-1 (NK6 homeobox 1) and SOX9), without obvious signs of endocrine or acinar differentiation, and is surrounded by mesenchymal cells ( Supplementary Fig. 1a ) 16 . For simplicity, we refer to this pancreatic MPC-enriched tissue as in vivo MPCs. Because human embryonic tissue is extremely limited and less amenable to perturbation studies, in parallel we used hESCs for in vitro differentiation of cells that express the same constellation of markers as in vivo MPCs ( Supplementary Fig. 1a ) 17 . We refer to these cells as in vitro MPCs. We carried out RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) analysis of in vivo and in vitro MPCs to profile polyadenylated transcripts, genomic sites bound by FOXA2 (a developmental TF that is specific to epithelial cells within the pancreas), and genomic regions enriched in the enhancer mark histone H3 monomethylated at Lys 4 (H3K4me1) (Fig. 1a and Supplementary Tables 1 and 2) .
Earlier studies have shown that hESC-derived pancreatic progenitors express appropriate markers [17] [18] [19] [20] . However, the extent to which they provide a suitable model to study global genome regulation of genuine pancreatic MPCs has not been tested. Several observations validated our artificial progenitors for this purpose, namely that in vitro MPCs recapitulated expression of known pancreatic MPC TFs ( Fig. 1b and Supplementary Fig. 1b) , that in vitro and in vivo MPCs showed a high correlation of transcript levels (Spearman's ρ = 0.5876, P < 2.2 × 10 −16 , Supplementary Fig. 1c ) and of transcript enrichment relative to other human tissues (Spearman's ρ = 0.5881, P < 2.2 Supplementary Fig. 1d ), and that the transcripts that are selectively enriched in either in vitro or in vivo MPCs relative to 22 non-pancreatic tissues (Fig. 1b) share common functional annotations, including pancreas development, chordate embryonic development and WNT signalling ( Fig. 1d and Supplementary Table 3 ). The enrichment of WNT signalling genes included numerous non-canonical WNT regulators, including FZD2, SFRP5, CELSR2 and VANGL2 (Fig. 1d and Supplementary Table 3) , whose orthologues have also been listed as selectively expressed in mouse embryonic pancreatic buds (Supplementary Table 4 ) 21, 22 , suggesting an evolutionarily conserved signalling mechanism operating in early pancreas development. This indicates that, despite the artificial origin of in vitro MPCs, and the presence of non-epithelial cell types in dissected embryonic pancreas, there are meaningful similarities in their transcriptomes. Integration of these data sets enabled us to define a core set of 500 genes that showed enriched expression in both sources of pancreatic MPCs (Supplementary Table 5 ), providing a resource to study genes important for early human embryonic pancreas development.
We next compared FOXA2 binding sites in the in vivo and in vitro pancreatic MPCs with other tissues where this TF is expressed (embryonic liver, adult liver and adult pancreatic islets; Fig. 1e,f) . FOXA2 largely bound to the same genomic regions in both sources of MPCs, yet bound to different genomic sites in other tissues, despite the fact that a similar sequence motif was recognized in all cases ( Fig. 1f and Supplementary Fig. 1e ). Furthermore, in vivo and in vitro MPCs shared cell-specific H3K4me1 enrichment at in vivo FOXA2-bound sites ( Fig. 1g and Supplementary Fig. 1f ). Finally, genes with two or more nearby H3K4me1-enriched FOXA2-bound regions in the in vivo MPCs showed enriched messenger RNA expression in both in vivo and in vitro MPCs relative to 23 control tissues (Fig. 1h) . Thus, in vitro and in vivo MPCs showed common FOXA2 and H3K4me1 occupancy patterns near pancreatic MPC-enriched genes. Taken together, our analyses suggest that artificial pancreatic MPCs recapitulate significant transcriptional and epigenomic features of genuine embryonic MPCs, and can thus be exploited as a tool to study genome regulation of human pancreas development.
An atlas of human pancreatic MPC enhancers
To map active cis-regulatory elements in human pancreatic MPCs, we employed in vitro MPCs to profile histone H3 acetylated at Lys 27 (H3K27ac), which marks active transcriptional enhancers 23, 24 . We then selected all genomic regions that showed H3K27ac and H3K4me1 enrichment in chromatin from in vitro MPCs, and that were also enriched in H3K4me1 in human CS16-18 pancreas (in vivo MPCs). After exclusion of annotated promoters, this disclosed 9,669 regions that carried an active enhancer chromatin signature in pancreatic MPCs ( Fig. 2a and Supplementary Fig. 2a ,b and Supplementary Table 6 ).
The cis-regulatory map included known pancreatic MPC enhancers (Fig. 2a) . As expected, predicted MPC enhancer sequences showed strong evolutionary conservation (Fig. 2b ), they were preferentially located near genes with increased expression in CS16-18 pancreas (Fig. 2c ) and they were often associated with core MPC-specific genes (hypergeometric test, P < 10 −15 ). In keeping with the cellular and temporal specificity of enhancers, 35% of pancreatic MPC enhancers showed no overlap with active enhancers from at least six of seven non-pancreatic tissues, and were thus defined as MPC-selective enhancers ( Fig. 2d and Supplementary Fig. 2c , Supplementary Tables 7 and 8) . Notably, 47% showed no overlap with enhancers from adult human islets 25 (Fig. 2d) . As expected from this cell-specific and stage-specific profile, genes near MPCselective enhancers are enriched in functions relevant for pancreas development ( Supplementary Fig. 2d and Supplementary Table 9 ). This analysis therefore uncovered a large collection of candidate active enhancers of the nascent human embryonic pancreas.
A combinatorial code for pancreatic MPC enhancers
To understand the regulatory sequence code that drives early human pancreas development, we examined this collection of MPC enhancers In and found that the most enriched sequence motifs match binding sites of known pancreatic regulators, including FOXA, HNF1, SOX, PDX1, GATA and ONECUT ( Fig. 3a and Supplementary Fig. 3a and Supplementary Tables 10 and 11 ). The single most enriched recognition motif, however, matched that of TEAD TFs, which have not been previously implicated in pancreas development (Fig. 3a) . 
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In vivo MPCs (a) Predicted enhancers were defined by enrichment in H3K27ac and H3K4me1 (see schematic representation in Supplementary Fig. 2b ). Shown are examples in the vicinity of PDX1, including a previously unannotated enhancer which we coin area V, upstream of known enhancers (areas I-IV; refs 41,42), and several enhancers near PRICKLE2, a non-canonical WNT signalling component (Supplementary Table 4 TEAD motifs were similarly enriched in regions bound by FOXA2 in CS16-18 pancreas as well as in vitro MPCs, but not in regions bound by FOXA2 in adult pancreatic islets or liver ( Fig. 3b and Supplementary Fig. 3b ). Because TFs are thought to function in a combinatorial manner, we identified combinations of multiple motifs that were most enriched at pancreatic MPC enhancers relative to non-pancreatic enhancers ( Fig. 3c and Supplementary Table 12 ). This showed that the most enriched combinations contained TEAD motifs adjacent to known pancreatic TF recognition sequences (Fig. 3c) . These results therefore revealed that pancreatic MPC enhancers contain combinations of motifs that match known as well as previously unrecognized pancreatic regulatory TFs.
TEAD1 is a core component of pancreatic progenitor cis-regulatory modules Table 2 ). On the basis of our computational predictions we also profiled TEAD1, a TEAD homologue that is highly expressed in MPCs from human embryonic pancreas ( Supplementary Fig. 4a ), defining binding sites for a total of six TFs in human MPCs (Fig. 4a) . All six TFs preferentially bound to known cognate recognition sequences that were widely distributed throughout the genome ( Supplementary Fig. 4b ), although there was marked preference for binding to MPC enhancers and annotated promoters (Fig. 4a,b and Supplementary Fig. 4c-d) . Furthermore, the six TFs very frequently co-occupied the same regions, predominantly at MPC enhancers (Fig. 4a,b and Supplementary Fig. 4c-e) . For example, enhancers bound by PDX1 and GATA6, the TFs with the lowest total number of binding sites, showed co-binding by at least one of the other five TFs in 94.5% and 95.3% of instances, respectively ( Supplementary  Fig. 4e ). Remarkably, TEAD1 showed a similar co-binding pattern as the five known pancreatic regulators analysed in this study ( Fig. 4c and Supplementary Fig. 4d, (Fig. 4f) . Altogether, computational and ChIP-seq analyses indicate that known pancreatic regulatory TFs show widespread co-binding at MPC enhancers, and that TEAD1 is an unexpected component of this combinatorial TF code.
Given the high degree of TF co-occupancy in MPC enhancers, we defined 2,945 regions within enhancers that are bound by two or more TFs, and coined these cis-regulatory modules (CRMs; Fig. 4a and Supplementary Fig. 4c ). CRMs provided greater spatial resolution of cis-regulatory sequences than H3K27ac/H3K4me1-enriched regions alone, which often appear to merge several adjacent evolutionary conserved sequences bound by multiple TFs.
A large number of CRMs mapped near known pancreatic regulatory genes, including HNF1B, FGFR2, HHEX, FOXA2, NKX6-1 and SOX9 (Fig. 4a and Supplementary Fig. 4c and Supplementary  Table 16 ). More generally, CRMs mapped near core MPC-enriched genes (P = 3.32 × 10 −12 ). Notably, spatial clusters of CRMs were associated with genes that were highly enriched in gene functions relevant for early pancreas development, including epithelial cell proliferation and WNT signalling ( Fig. 4g and Supplementary Tables 17 and 19) . Notably, non-canonical WNT regulatory genes were enriched near clusters of CRMs (P = 1.18 × 10 −9 ; Supplementary Table 19 ), in agreement with our transcriptome analysis of pancreatic MPCs (Fig. 1c and Supplementary Table 4 ) and transcriptome analysis of mouse pancreas development 21, 22 . Interestingly, CRMs bound by any of the six TFs were associated with the same functional annotations (Fig. 4g ). This included TEAD1-bound CRMs, despite the fact that this TF is widely expressed across multiple tissues and developmental stages (Fig. 4g ). TEAD1-bound CRMs thus mapped to known or plausible pancreatic regulatory genes, including FGFR2, RBPJ, FZD5/7/8, FRZB, JAG1, CDC42EP1, MAP3K1, NKX6-1, HHEX, GATA4, GATA6, FOXA2, HES1 and SOX9 ( Fig. 4a and Supplementary Fig. 4c and Supplementary Table 20) . This is consistent with a broad combinatorial function of regulatory TFs in the establishment of the MPC-specific transcriptional programme.
To functionally validate these human embryonic pancreas CRMs, 32 sequences were transfected into in vitro MPCs, and 20 (62.5%) yielded significant enhancer activity (Mann-Whitney test for CRMs versus control regions, P = 0.0144; Fig. 5a and Supplementary Fig. 5a ).
To directly test the function of TEAD1 binding to CRMs, we mutated TEAD recognition sequences in three CRMs that were bound by TEAD and other pancreatic TFs, which disrupted enhancer activity in all cases (Fig. 5b) .
We selected ten CRMs for validation using zebrafish transgenesis, and in eight cases we demonstrated enhancer activity in Pdx1 + /Nkx6.1 + pancreatic endoderm MPCs ( Fig. 5c -e, Supplementary Fig. 5b and Supplementary Table 21 ). Amongst these, we examined a CRM in the locus encoding SOX9, an essential regulator of the self-renewal of mouse pancreatic MPCs that is mutated in humans with pancreas hypoplasia 13,14 ( Fig. 5c,d ). This CRM showed pancreasspecific enhancer activity in zebrafish transgenics, whereas mutation of the TEAD recognition sequence abolished enhancer activity, providing further confirmation that TEAD1 binding is required for the in vivo function of pancreatic MPC enhancers (Fig. 5c ).
Taken together, this analysis provided a rich source of cis-regulatory elements in human embryonic pancreatic progenitors. It also revealed widespread co-occupancy of pancreatic developmental TFs at MPC enhancers, and uncovered TEAD as a hitherto unrecognized core component of this combination of TFs.
TEAD and YAP regulate a pancreatic developmental programme
We next examined TEAD-dependent gene regulation during pancreas development. TEAD proteins interact with the active nuclear form of the coactivator Yes-associated protein (YAP). YAP is negatively regulated by Hippo signalling, which triggers YAP phosphorylation 
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Fold enrichment over randomized FOXA2 sites Supplementary  Table 15 ). (f) TEAD1 binding is enriched in regions bound by FOXA2 in either in vitro or in vivo MPCs. We calculated TEAD1-FOXA2 co-binding over the median expected value after generating 1,000 permutations of in vitro or in vivo FOXA2 peak positions. (g) CRMs underlie a pancreas developmental regulatory network. The 2,956 genes associated with CRMs were functionally annotated using GREAT (ref. 53) , and REVIGO (ref. 54 ) was used to visualize annotation clusters. The most significant terms from each cluster are highlighted according to the P-value colour scale. Bar graphs show that Gene Ontology (GO) terms are similarly enriched in CRMs bound by different TFs. * Several WNT-pathway-related terms were enriched, although manual annotation in this category revealed that most genes were either non-canonical WNT signalling mediators or antagonists of canonical WNT signalling (full annotations in Supplementary Table 17) . 48 hpf neg. (Fig. 7e ) was fused to a minimal promoter and green fluorescent protein (GFP), and injected into zebrafish embryos. In (c), a SOX9 CRM drove strong GFP expression in the pancreatic domain of 48 hpf zebrafish embryos (dotted circle, left panel), which was disrupted by a mutation in the TEAD recognition sequence (right). A midbrain-specific enhancer was used as an internal control for transgenesis. Note that this experiment assessed the activity of a single SOX9 CRM, which does not necessarily fully recapitulate the expression of endogenous sox9b. In the graph, +, +/− and − represent strong, weak and absent GFP expression in the pancreatic domain, respectively (n = 110-140 embryos per condition, chi-squared test P = 1.37 × 10 −83 . We examined nuclear localization of YAP throughout differentiation, and found that YAP was highly expressed in the nucleus of hESCs, and subsequently showed low yet detectable immunoreactivity throughout intermediary stages of the in vitro pancreatic differentiation protocol ( Supplementary Fig. 6a ), as well as in the nucleus of dorsal foregut epithelial cells of CS10 human embryos ( Supplementary Fig. 6b ). Strong YAP expression was subsequently observed in the nucleus of in vitro-derived pancreatic MPCs, as well as human and mouse in vivo pancreatic MPCs (CS18 and embryonic day 10.5 (E10.5)-E14.5 embryos, respectively; Fig. 6a and Supplementary Fig. 6c-f,h ), in keeping with recent descriptions in mice 28 . By contrast, YAP immunoreactivity was undetectable or delocalized to the cytoplasm in NGN3
+ endocrine-committed progenitors, differentiated acinar cells or endocrine cells (Fig. 6b,c and Supplementary Fig. 6c-g,i) , although nuclear expression was maintained in ductal cells (Supplementary Fig. 6f ). Furthermore, in pancreatic MPCs YAP bound to most tested TEAD1-bound regions (Fig. 6e) , similar to what has been observed in other cell types that exhibit nuclear YAP expression 27 . Thus, during embryonic pancreas development the coactivator YAP shows stagespecific nuclear localization in MPCs. This suggests a YAP-dependent function of TEAD1 during early pancreas development that is confined to MPCs, and is then inactivated on differentiation of pancreatic lineages.
To study YAP-dependent TEAD function in pancreatic MPCs, we first used verteporfin (VP), a chemical compound that disrupts the TEAD-YAP complex 29 . VP treatment of human in vitro MPCs and pancreatic bud explants dissected from E11.5 mouse embryos and grown ex vivo caused decreased expression of a subset of genes associated with TEAD1-bound enhancers, including genes that are established critical regulators of progenitor cell growth in the embryonic pancreas, such as FGFR2 (ref. Supplementary Fig. 4f ). Consistently, exposure of mouse explants to VP for 24 h significantly reduced epithelial cell proliferation by 39% (P = 0.006; Fig. 7c ) and limited the growth of pancreatic buds to 27% of control organs after 3 days in culture (P = 0.038; Fig. 7d ). These results suggest that the TEAD-YAP complex has direct effects on several known regulators of pancreatic progenitors, and is required for the proliferation and growth of early embryonic pancreas epithelium.
To further test the in vivo function of YAP and TEAD in pancreas development, we carried out genetic perturbations in zebrafish. In keeping with our chemical inhibition studies, morpholino inhibition of yap1 caused a reduction in the pancreas size at 48 hours post fertilization (hpf), with hypoplasia in 65% of embryos (n = 46; Supplementary Fig. 7a) , and a marked reduction of sox9b-expressing pancreatic MPCs (Fig. 7f,g ). This effect was partially rescued by coinjection with yap1 mRNA, confirming the morpholino specificity ( Supplementary Fig. 7a ). In agreement, zebrafish embryos expressing a TEAD protein fused to the transcriptional repressor domain of Engrailed (TEAD-EnR) (ref. 32) phenocopied the morpholino inhibition of yap1 ( Fig. 7g and Supplementary Fig. 7a ). In summary, inhibition of Yap1 and TEAD proteins in zebrafish suppressed pancreatic sox9b expression and cell growth, in agreement with our mouse and human in vitro studies. Given that TEAD directly regulates a SOX9 enhancer (Fig. 5c) , and that SOX9 regulates mouse and human pancreatic MPC growth 13, 14, 31 , we hypothesize that the effects of TEAD and YAP on pancreatic progenitors are partially mediated through SOX9. Taken together, genetic and chemical inhibitor experiments support a model whereby YAP co-activation of TEAD1-bound MPC enhancers regulates a genomic regulatory programme that is required for the expression of stage-specific genes and for the outgrowth of pancreatic progenitors.
DISCUSSION
We have created and validated a map of active enhancers in human embryonic pancreatic progenitors. This effort expands the current list of known active enhancers in the embryonic pancreas from a handful of examples to thousands of stage-specific cisregulatory elements. This included clustered enhancers, which were linked to a core cell-specific transcriptional programme, in analogy to earlier studies in diverse cellular lineages 25, 33 . Our studies also show that pancreatic embryonic progenitor cells derived from hESCs mimic salient transcriptional and epigenomic features of pancreatic progenitors from human embryos, illustrating the power of pluripotent stem cell biology to dissect regulatory mechanisms underlying human embryogenesis.
This atlas of pancreatic MPC enhancers should facilitate the discovery of non-coding mutations that cause human diseases linked to abnormal pancreas development. In support for this claim, H3K4me1-, PDX1-and FOXA2-binding data from in vitro MPCs enabled the identification of recessive mutations that map to a previously unannotated enhancer of PTF1A and cause isolated pancreas agenesis 34 . Sequence variation in MPC enhancers could hypothetically increase the susceptibility to type 2 diabetes mellitus by impacting pancreas development and thereby affecting the pancreatic beta cell mass. Finally, germ-line or somatic variants in MPC enhancers could also influence the development of pancreatic adenocarcinoma, which has been associated with dedifferentiation of adult exocrine cells 35, 36 and with YAP activation 37, 38 . Our study identifies binding sites of several TFs that are known to be essential for early pancreas development, and show that they co-occupy pancreatic MPC enhancers, consistent with a combinatorial TF code. Unexpectedly, our results revealed that TEAD proteins-exemplified by TEAD1-and the coactivator YAP are central components of this combinatorial code, activating key regulatory genes and promoting the outgrowth of pancreatic MPCs.
The TEAD-dependent transcriptional mechanism provides a means for signal-responsive dynamic regulation of MPC enhancers during pancreas development. The coactivator YAP is a component of the Hippo signalling cascade, which phosphorylates YAP, leading to its retention in the cytoplasm or to its degradation 39 . Our data shows that, as human pancreatic MPCs transition to endocrine and acinar lineages, YAP undergoes immediate nuclear exclusion and downregulation. On the basis of our chemical and genetic experiments, this dynamic change is expected to lead to inhibition of MPC enhancers during pancreatic differentiation.
Two recent reports showed that pancreas-specific disruption of the upstream Hippo kinases Mst1/2 leads to increased proliferation of adult acinar pancreatic cells, which acquire a duct-like morphology, exhibit increased nuclear localization of Yap and show ectopic expression of the TEAD target Sox9 (refs 28,40). These observations do not address whether Hippo signalling or TEAD are important for pancreatic progenitors, but they are consistent with failed suppression of a progenitor programme in adult cells, and therefore support the predictions from our findings. Collectively, existing data suggest a model whereby TEAD proteins provide a regulatory switch that activates a stage-specific transcriptional programme in pancreatic MPCs, and facilitates signal-responsive inactivation of this programme during pancreatic cell differentiation (Fig. 8) .
Further studies should explore this regulatory mechanism in human disease. The reactivation of the YAP-TEAD-dependent MPC enhancer programme in adult acinar cells could conceivably activate a progenitor-like cellular programme during early stages of pancreatic carcinogenesis 35, 36 , and/or contribute to YAP-dependent cancer Injection of yap1 morpholino oligonucleotide (yap1-MO) caused a reduction or absence of sox9b mRNA in the pancreatic domain (p; arrow) in 50/102 48 hpf embryos. Control embryos showed pancreatic sox9b expression in 100/100 embryos (chi-squared P = 2.61 × 10 −15 ). Note that control and morphant embryos always showed sox9b expression in fin buds (fb). (g) Injection of yap1-MO (n = 10 embryos) or the TEAD-EnR dominant negative (n = 12 embryos) caused a decreased number of sox9b + /Pdx1 + pancreatic progenitors (dotted lines) in 24 hpf embryos versus controls (n = 9 embryos). Sox9b was detected by in situ hybridization and Pdx1 by immunofluorescence. The graph reflects the total number of pancreatic progenitors in each embryo. yap1-MO also increased ectopic expression of pancreatic markers Supplementary Fig. 7b ). Student's t-test P-values and s.d. are shown. . This same genetic programme could potentially be exploited to control growth and differentiation during the generation of artificial pancreatic cells.
METHODS
Methods and any associated references are available in the online version of the paper. Human embryonic pancreas and liver were dissected at CS16-18, which correlates to ∼37-45 days post-conception. These stages were the earliest at which pancreatic epithelial cells could be efficiently dissected away from surrounding mesenchyme with minimal contamination. After isolation tissues were rinsed with PBS, incubated for 10 min in 1% formaldehyde and 5 min in 125 mM glycine, rinsed in PBS containing protease inhibitor cocktail (Roche) at 4 • C, and snap-frozen and stored at −80 • C. RNA was extracted using TRIzol and DNase.
Human ESCs (H9, WiCell) were imported under guidelines from the UK Stem Cell Bank Steering Committee (SCSC10-44). Differentiation of pancreatic MPCs has been described 17 . Briefly, definitive endoderm was induced by growing hESCs in AFBLy: chemically defined medium with polyvinyl alcohol (CDM-PVA) + activin A (100 ng ml −1 ), BMP4 (10 ng ml −1 ), basic fibroblast growth factor (bFGF; 20 ng ml −1 ) and LY294004 (10 µM). The CDM-PVA AFBLy cocktail was replenished daily, and daily media changes were made until differentiation day 10. After the definitive endoderm stage (days 1-3), cells were cultured in Advanced DMEM (Invitrogen) with SB-431542 (10 µM; Tocris), FGF10 (50 ng ml −1 ; Autogen Bioclear), all-trans retinoic acid (2 µM; Sigma) and Noggin (150 ng ml −1 ; R&D Systems) during days 4-6. For days 7-9, cells were supplemented with human FGF10 (50 ng ml −1 ; Autogen Bioclear), all-trans retinoic acid (2 µM; Sigma), KAAD-cyclopamine (0.25 µM; Toronto Research Chemicals) and Noggin (150 ng ml −1 ; R&D Systems). On days 10-12, cells were cultured in human FGF10 (50 ng ml −1 ; Autogen Bioclear), alltrans retinoic acid (2 µM; Sigma), and KAAD-cyclopamine (0.25 µM; Toronto Research Chemicals).
For RNA-seq and ChIP-seq, cells from three independent differentiation experiments were pooled. For ChIP, cells were fixed as described above, snapfrozen and kept at −80 • C. Total RNAs were extracted from hESCs or differentiated progenitors using the RNeasy Mini Kit (Qiagen) and treated with RNase-free DNase (Qiagen).
Immunolocalization.
Immunolocalization was carried out as described 16, 17, 44, 45 . Antibodies are listed in Supplementary Table 23 .
Pancreatic explants from E12.5 C57BL/6 mouse embryos and whole-mount stainings were carried out as described 46 with modifications. Briefly, pancreases were fixed for 20 min in 4% paraformaldehyde, blocked in 0.5% Triton X-100/10% fetal bovine serum (FBS)/PBS overnight at 4 • C and incubated for 24 h with primary antibody at 4 • C then overnight with secondary antibody at 4 • C, and finally DAPI stained. EdU staining was carried out using a Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen). All images presented show representative results obtained from at least three independent experiments.
ChIP. Either seven human CS16-18 pancreatic buds, four CS16-18 liver buds (as described above) or about 10 million cells from a pool of three pancreatic progenitor in vitro differentiation experiments were pooled in 1 ml of lysis buffer containing protease inhibitor cocktail (Roche) and sonicated for 10-15 cycles essentially as described 25, 47 . We verified that a substantial portion of chromatin fragments were in the 200-600-bp range by gel electrophoresis.
ChIP was carried out with 50-300 µl of sonicated chromatin as described 25, 48, 49 , with minor modifications. Briefly, sonicated chromatin was diluted with ChIP dilution buffer (0.75% Triton X-100, 140 mM NaCl, 0.1% sodium deoxycholate, 50 mM HEPES at pH 8.0, 1 mM EDTA, 1× protease inhibitor cocktail) to achieve a final SDS concentration of 0.2%, pre-cleared with A/G Sepharose beads (GE Healthcare) for 1 h, incubated overnight at 4 • C with 1-1.5 µg antibodies (Supplementary Table 23 51 . For a global comparison of gene expression profiles ( Supplementary Fig. 1c) , we analysed 44,699 UCSC gene variants expressed at more than 5 FPKM in at least one sample. Expression values were median-centred and scaled by the root mean square. Spearman's correlation values were calculated for each pair.
RNA enrichment analysis. Tissue selectivity of each transcript was assessed by
computing the FPKM CV in the 25 samples described in Supplementary Table 1 . To obtain the enrichment of each transcript in each tissue, we calculated Z-scores as the difference between the log 2 -transformed expression level in the specific tissue and the mean of all tissues, divided by the standard deviation. For detection of MPCspecific transcripts, Z-score measurements were calculated without data from islets and either in vitro or in vivo MPCs. We defined tissue-specific genes as those with CV ≥ 1, expression ≥ 0.3 FPKM and Z-score ≥ 1 in any tissue.
Core MPC-specific genes were defined as UCSC-annotated genes that were tissue selective (CV ≥ 1) and enriched in in vitro MPCs (Z-score ≥ 1). We then sorted by in vivo MPC enrichment Z-score, and selected the top 500 (Supplementary Table 5 ).
Functional annotations. Transcript functional annotation was carried out with DAVID (ref. 52), using GO Biological Process (FAT), Pathways (KEGG, Panther) and annotation clustering. In Fig. 1c , we sorted terms by P-value and show the most significant term of each cluster. Annotations are provided in Supplementary Table 3 .
Genes associated with enhancers and CRMs were analysed with GREAT v2.0.2 (ref. 53 ) applying default settings (basal plus extension; significant by both binomial and hypergeometric tests), and annotated with GO Biological Process plus all pathway annotations. Raw binomial P-value and binomial fold enrichment were used to present enrichments. Supplementary Tables 9, 17 and 19 list annotations associated with MPC-selective enhancers, CRMs and CRM clusters, respectively. GO Biological Process terms were further processed with REVIGO (ref. 54 ; 0.9 allowed similarity; term size database-whole UniProt; semantic similarity measurenormalized Resnik; cluster definition default parameters) taking the most significant term in each GO cluster.
ChIP-seq.
Chromatin from replicate pools of in vitro MPCs was used for FOXA2 and H3K4me1 ChIP-seq experiments. Single libraries were prepared from chromatin pools for all other ChIP-seq experiments, except for FOXA2 in vivo MPC, in which libraries from two experiments were sequenced and reads were pooled for alignment. All libraries were prepared with 5-10 ng DNA, sequenced with the Illumina HiSeq 2000 platform and aligned to NCBI36/hg18 using Bowtie v0.12.7 (Supplementary Table 2 ), allowing unique alignment with at most one mismatch. Post-alignment processing included in silico extension, signal normalization based on the number of millions of mapped reads, extension to MACS fragment size estimation (v1.4.0beta) and retention of only unique reads. For signal normalization, the number of reads mapping to each base in the genome was counted with genomeCoverageBed (bedtools v2.17.0). TF enrichment sites were detected with MACS v1.4.0beta using default parameters and P < 10 −10 . The background model was defined with the input DNA sequence. SICER v1.03 was used to call H3K4me1-enriched islands with window size 100 bp, gap size 800 bp and fragment size estimated by MACS v1.4.0beta. Enriched islands were called at false discovery rate (FDR) < 10 −3 . For H3K27ac-enriched regions gap size was 200 bp. For replicate samples we retained overlapping peaks/islands in replicates. To compute FOXA2 and H3K4me1 signal correlations between duplicates we divided the genome into 1 or 5 kilobase (kb) bins, respectively, then counted unique reads in each bin and quantile-normalized results. Bins with values less than the fifth percentile in both samples were excluded from the analysis. Pearson correlation values were 0.8-0.9 in all biological replicates (Supplementary Fig. 1g ). Public data sets were processed identically (listed in Supplementary Table 2 ).
TF and H3K4me1 aggregation plots. To compute aggregation plots (Fig. 1f), we first selected 'tissue-specific regulatory regions' , defined by the intersections of H3K4me1 islands with TF 'peaks' in the same tissue. The resulting numbers of regions were as follows: FOXA2 in in vivo MPCs, 2,307; SOX2 in hESCs, 5,749; MEIS1 in CD133 + cells, 2,210; DNase I peaks containing ETS1 motifs in mammary epithelial cells, 14,100, and DNase I peaks containing MEF2A motifs in myotube cells, 13,614. Next, regions spanning ±3 kb from the centre of TF peaks were divided into 100-bp bins. The coverage signal was obtained using coverageBed (bedtools v2.17.0). Data were quantile normalized after creating 100-bp bins in H3K4me1 islands from each tissue.
Clustering. To compare ChIP-seq signals between tissues (Fig. 1e and Supplementary Fig. 1f ), we generated 6-kb windows centred on in vivo MPC FOXA2 peaks. Each window was divided into 100-bp bins and binned signal coverage was quantile normalized as described above. Hierarchical clustering was carried out with Cluster3 (ref. 55 ) with similarity metric set to Correlation (uncentred) and average linkage as the clustering method. Heat maps were visualized with TreeView 56 .
Definition of enhancers and CRMs. Enhancers were defined as H3K27ac islands
in the in vitro MPCs that overlapped H3K4me1 islands in both in vitro and in vivo MPCs. We discarded regions overlapping promoters (1 kb upstream and 2 kb downstream of RefSeq transcription start sites) or less than 50 bp. Enhancers in eight control tissues were defined with analogous criteria based on H3K27ac and H3K4me1 islands (Supplementary Table 8 ).
To define CRMs we merged all in vitro MPC TF peaks that were less than 500 bp apart, and retained 2,945 regions bound by at least two different TFs that overlapped MPC enhancers by at least 1 bp.
Clusters of CRMs were defined as described 25 , essentially as any group of at least three CRMs in which all adjacent CRMs were separated by less than the 25th percentile of chromosome-specific randomized distances.
Enhancer selectivity. MPC-selective enhancers were defined as those that showed no overlap with an enhancer from at least six out of seven control tissues (hESCs, fetal muscle, fetal stomach, fetal thymus, mammary epithelial cells, myotubes and osteoblasts). All possible combinations of three motifs from the 23 enriched motifs contained within 500-bp regions were computed in MPC enhancers versus enhancers from eight other tissues. We calculated eight MPC versus control tissue fold enrichment and P-values (chi-squared test), and then combined them in a unique P-value for each motif combination with a Z-weighted method 59 . Supplementary Table 12 shows the top 50 most enriched combinations.
For TF peaks, HOMER analysis was carried out in 200-bp windows centred on peak summits and motif lengths were set to 8, 10 and 12 bp. Co-enriched motifs were manually curated to exclude redundant motifs. Known DNA-binding motifs were associated with the de novo recovered matrix only if the HOMER score was more than 0.7.
Binding and co-binding enrichment analysis. To assess the enrichment of TF binding and co-binding in enhancers or promoters, the positions of the enhancers or promoters were randomized in all mappable hg18 coordinates using shuffleBed (bedtools v2.17.0). Mappable regions were defined as those not annotated as genome gaps and with a score of 1 in the CRG mappability 50-bp track of the UCSC browser 60 . Binding enrichment was calculated over the median of 1,000 permutations.
Co-bound regions were defined with intersectBed (bedtools v2.17.0) as regions bound by at least two TFs. To calculate TF co-binding enrichment, we shuffled each TF individually in the mappable genome, and calculated the overlap with sites bound by the other TFs (median of 1,000 permutations generated by shuffleBed, bedtools v2.17.0). A chi-squared test was applied to assess the enrichment of each combination of two TFs over expected co-binding. For comparison, we applied the same pipeline to define 'co-binding' between MEIS1 in CD133 + cells and the six MPC TFs (Supplementary Table 2 ).
Enhancer function assays in human cells. The pGL4.23[luc2/minP] vector (Promega) was modified by inserting a Gateway cassette upstream of the minimal promoter (pGL4.23-GW) for subsequent cloning of CRMs and control sequences. These 500-2,000-bp sequences were amplified from human genomic DNA with Phusion High-Fidelity DNA Polymerase (New England Biolabs), cloned into pENTR/D-TOPO (Invitrogen), shuttled into pGL4.23-GW and assessed by Sanger sequencing and restriction enzyme digestion. To mutate CRMs, we replaced a 3-bp sequence of the core of TEAD motifs, as this was previously shown to disrupt TEAD binding 27 , and confirmed by Sanger sequencing. Oligonucleotides are available in Supplementary Table 15 .
At day 10 of the differentiation protocol, cells were transfected in 24-well plates with pGL4.23-CRM plasmids (400 ng) and Renilla normalizer plasmid (4 ng) using Lipofectamine 2000 (Invitrogen). Luciferase was measured at day 13 with a DualLuciferase Reporter Assay System (Promega). The results shown represent the average and s.e.m. of three (HMGA2, GLIS3 and MAP3K10) or four (all other CRMs and all negative controls) independent transfections per construct. Eight of 32 plasmids in Fig. 5a and Supplementary Fig. 5a , and six of the nine CRMs in Fig. 5b , were retested in independent experiments that yielded comparable results. Statistical significance was assessed with a two-tailed Student t-test using all experiments (Supplementary Table 22 ).
Pancreatic explant experiments.
Mouse experiments were approved by the Comitè Étic d'Experimentació Animal (University of Barcelona) in accordance with national and European regulations. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments or outcome assessment. Pancreatic explants were carried out as described 61 with minor modifications. Dorsal pancreatic buds from E11.5 CD-1 mouse embryos were cultured in RPMI medium with 10% FBS for 16 h (day 1) before VP 0.1 µM (Atomax) or DMSO (control) treatment 24 h in RPMI 3% FBS. After 24 h (day 2), the drug was washed out and buds were cultured for 1 day in RPMI 10% FBS (day 3).
For quantification of explant growth we used Sox9-eGFP transgenic embryos, which enabled visualization of pancreatic epithelial progenitors. We used ImageJ 1.46a to measure the area of eGFP-expressing cells on days 1 and 3. We carried out three independent experiments, and examined two to three pancreases per condition in each experiment. We expressed areas as percentage of the baseline in the same explant, and used the Mann-Whitney test to determine significance. Data failed to show normal distribution with the Kolmogorov-Smirnov test.
To study epithelial cell proliferation, explants were exposed to EdU (1 µM) after VP treatment for 30 min and analysed 24 h later. We examined two to four pancreases per condition in each of three independent experiments. The MannWhitney test was used for statistical significance.
We obtained RNA from pools of at least three pancreatic buds using the RNeasy Mini Kit (Qiagen), and collected three separate pools from independent experiments. qPCR with reverse transcription (qRT-PCR) was carried out using a 7300 Real Time PCR System (Applied Biosystems) and Power SYBR Green PCR Master Mix (Applied Biosystems). Each sample pool was amplified in duplicate using Gapdh for normalization. Oligonucleotides are shown in Supplementary Table 15 . Statistical significance was assessed with a two-tailed Student t-test.
VP experiments in human progenitors. In vitro MPCs were subjected to VP (10 µM) or DMSO treatment for 16 h in duplicate on day 12 of the differentiation protocol. The drug was washed out with PBS and RNA was extracted with an RNeasy Mini Kit (Qiagen). Reverse transcription was carried out with 0.5 µg RNA using Superscript II (Invitrogen) and qPCR was carried out using SensiMix (Quantace). Oligonucleotide sequences are listed in Supplementary Zebrafish experiments. Zebrafish embryos from the same cross were randomly selected for the control, morphant (yap1-MO), dominant negative (TEAD-EnR) and rescue (yap1-MO + yap1 mRNA) conditions. Five nanolitres of 2 mM morpholino targeting a splice junction of yap1 (yap1-MO, 5 -AGCAACATTAACAACTCAC TTTAGG-3 ; previously reported 62 ) were injected into the yolk of one-to twocell stage zebrafish embryos. Morpholino activity was confirmed by qRT-PCR (oligonucleotides 5 -TGCCAGACTCATTCTTCACG-3 , 5 -TGGGAACCTTGC TTTACTGG-3 ). For rescue experiments, yap1 mRNA (50 pg) was co-injected with the morpholino. The mRNA of mouse Tead2 fused with Engrailed repressor domain (TEAD2-EnR) was synthesized using an existing vector 52 , and 200 pg was injected into the yolk of one-to two-cell stage zebrafish embryos. Embryos were fixed overnight at 4 • C in 4% paraformaldehyde in PBS. In situ hybridization for Sox9b (ref. 63 ) and insulin 64 was carried out as described 65 and revealed with NBT/BCIP substrate in 46-71 embryos per condition. After in situ hybridization, immunolocalization was carried out for some embryos using antibodies listed in Supplementary Table 23 . The number of Pdx1 + /Sox9b + pancreatic progenitors was counted in each embryo using confocal microscopy, and differences between groups were analysed with a two-tailed Student t-test.
For transgenic analysis of wild-type and mutant CRMs, zebrafish embryos from the same cross were randomly selected. DNA fragments were recombined to an enhancer test vector that is sequentially composed of a Gateway cassette for insertion of CRMs, a gata2 minimal promoter, an enhanced GFP reporter gene and a strong midbrain enhancer (z48) that works as an internal control for transgenesis. All these elements have been previously reported 66 and were assembled in a tol2 transposon 67 . Transgenesis was carried out as described 66 and embryos were grown to 24 and 48 hpf at 28 • C. GFP was documented using an epifluorescence stereomicroscope. Embryos positive for transposon integration were immunostained for simultaneous detection of Nkx6.1 plus either Pdx1 or insulin expression to identify pancreatic progenitors by confocal microscopy. Note that in zebrafish Nkx6.1 is expressed in pancreatic MPCs but not in endocrine cells, unlike mammalian embryos 68 . For each construct we counted embryos with GFP expression in Nkx6.1 + pancreatic cells (Supplementary Table 21) .
No statistical method was used to predetermine sample size. The investigators were not blinded to allocation during experiments or outcome assessment. Figure 5c shows representative data from one independent experiment with 110-140 zebrafish embryos per condition. Figure 7g shows representative data from one independent experiment with 9-12 zebrafish embryos per condition. Supplementary Fig. 4a shows representative data from six independent experiments. Three immunostainings were carried out independently for two human embryos (CS18 and CS19). Supplementary Fig. 7a shows representative data from one independent experiment with 46-71 zebrafish embryos per condition.
Reproducibility of experiments.
Accession numbers. Primary data sets generated here are available at ArrayExpress under accession numbers E-MTAB-1990 and E-MTAB-3061. Referenced data sets are listed in Supplementary Tables 1 and 2 Table 8 ). Each pie chart shows in red the proportion of MPC enhancers that are inactive in each tissue. We defined MPC-selective enhancers as those that were inactive in at least 6 out of 7 non-pancreatic tissues. FA  T8  P  T  A4  A  HMGA2  MAP3K1  IRS1  CTNND2  FOXA2  VEG  BMP2  KR  AMB  DKK2  PDX1  CALB1  FGFR2  NKX6.1  SPINK  HNF1B  AMO  HHEX  RBPJ  SOX4  RFX6  JAG1  GAT  ADAMTS16  MEIS1  LAMB1  GLIS3  HES1  PRKAR1  SOX9  MAPK10 
